[
  {
    "ts": null,
    "headline": "Gilead to Invest $11 Billion to Bolster Domestic Operations",
    "summary": "Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration.  Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion.  The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=c743ab4ec8478c3e28465e30bd0602a707723a24fcdf92dd1e9e4c6e681ed874",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746654401,
      "headline": "Gilead to Invest $11 Billion to Bolster Domestic Operations",
      "id": 134316973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration.  Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion.  The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=c743ab4ec8478c3e28465e30bd0602a707723a24fcdf92dd1e9e4c6e681ed874"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing",
    "summary": "Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.",
    "url": "https://finnhub.io/api/news?id=8b6282782e450651ee918a109dcceaf868a8aa0d68bbb08afc9d6271c5739366",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746646654,
      "headline": "Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing",
      "id": 134316974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.",
      "url": "https://finnhub.io/api/news?id=8b6282782e450651ee918a109dcceaf868a8aa0d68bbb08afc9d6271c5739366"
    }
  },
  {
    "ts": null,
    "headline": "Gilead boosts planned US investments by $11 billion amid tariff threat",
    "summary": "The new investments, unveiled on Wednesday, will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said.  These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said.  Major U.S. drugmakers, including Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb, have also recently announced additional investments to boost domestic production amid the tariff threat.",
    "url": "https://finnhub.io/api/news?id=20dbd094f44d1f40e7260dd7ce2618ead8b48dc12ecd893d8cd897d9bef2278d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746643954,
      "headline": "Gilead boosts planned US investments by $11 billion amid tariff threat",
      "id": 134316975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The new investments, unveiled on Wednesday, will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said.  These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said.  Major U.S. drugmakers, including Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb, have also recently announced additional investments to boost domestic production amid the tariff threat.",
      "url": "https://finnhub.io/api/news?id=20dbd094f44d1f40e7260dd7ce2618ead8b48dc12ecd893d8cd897d9bef2278d"
    }
  },
  {
    "ts": null,
    "headline": "Trump to sign order on drug prices as early as next week, Politico reports",
    "summary": "U.S. President DonaldTrump is expected to sign an executive order as early as nextweek that would revive an effort to decrease drug costs by tyingthe amount the government pays for some medicines...",
    "url": "https://finnhub.io/api/news?id=60016d3eee6537ed9d289be60551127d22a74d714c14ce0826cb2c502edd1eb4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746639499,
      "headline": "Trump to sign order on drug prices as early as next week, Politico reports",
      "id": 134310100,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "U.S. President DonaldTrump is expected to sign an executive order as early as nextweek that would revive an effort to decrease drug costs by tyingthe amount the government pays for some medicines...",
      "url": "https://finnhub.io/api/news?id=60016d3eee6537ed9d289be60551127d22a74d714c14ce0826cb2c502edd1eb4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025",
    "summary": "Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market...",
    "url": "https://finnhub.io/api/news?id=9d01c9ecea9adc27ade881c4133821b9ced55d8f165bacc21b6fcbefc1552664",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746639112,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025",
      "id": 134316976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market...",
      "url": "https://finnhub.io/api/news?id=9d01c9ecea9adc27ade881c4133821b9ced55d8f165bacc21b6fcbefc1552664"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=8df2056d7e779f255a13588decdfb13dd76e739bf3c791409da34147bb739b4f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746635820,
      "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 134343020,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=8df2056d7e779f255a13588decdfb13dd76e739bf3c791409da34147bb739b4f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead announces $11 billion in new investments in US",
    "summary": "Gilead Sciences announced $11billion in new planned investment in the U.S. to boost itsdomestic manufacturing and research heft, becoming the latestcompany to announce spending plans in reaction to...",
    "url": "https://finnhub.io/api/news?id=ef10826cdca3565f2a2df066d9aa011754b645d62319536e22448a9b71c37990",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746630248,
      "headline": "Gilead announces $11 billion in new investments in US",
      "id": 134299898,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences announced $11billion in new planned investment in the U.S. to boost itsdomestic manufacturing and research heft, becoming the latestcompany to announce spending plans in reaction to...",
      "url": "https://finnhub.io/api/news?id=ef10826cdca3565f2a2df066d9aa011754b645d62319536e22448a9b71c37990"
    }
  },
  {
    "ts": null,
    "headline": "Gilead To Invest $32 Bln In U.S. Manufacturing And R&D Through 2030",
    "summary": "Gilead Sciences Inc: * GILEAD TO INVEST $32 BILLION IN U.S. MANUFACTURING ANDRESEARCHAND DEVELOPMENT THROUGH 2030 AND CREATE MORE THAN 3,000 DIRECTAND INDIRECT JOBS BY 2028 ...",
    "url": "https://finnhub.io/api/news?id=099265c5920f0f55b9f11745a909bef0895bb183e1499712e96e68f0dd180eb8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746629050,
      "headline": "Gilead To Invest $32 Bln In U.S. Manufacturing And R&D Through 2030",
      "id": 134298530,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences Inc: * GILEAD TO INVEST $32 BILLION IN U.S. MANUFACTURING ANDRESEARCHAND DEVELOPMENT THROUGH 2030 AND CREATE MORE THAN 3,000 DIRECTAND INDIRECT JOBS BY 2028 ...",
      "url": "https://finnhub.io/api/news?id=099265c5920f0f55b9f11745a909bef0895bb183e1499712e96e68f0dd180eb8"
    }
  },
  {
    "ts": null,
    "headline": "2024 Total Dividend Income And Portfolio Update",
    "summary": "2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.",
    "url": "https://finnhub.io/api/news?id=e84a491388932db92b15edae67d11240e3b812c212aa814a6209bef6a4a9af74",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746617700,
      "headline": "2024 Total Dividend Income And Portfolio Update",
      "id": 134296532,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2007398242/image_2007398242.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "2024 also saw some changes to some of my holdings as the author shuttled several dividend income payers for higher return crypto plays. Click to read.",
      "url": "https://finnhub.io/api/news?id=e84a491388932db92b15edae67d11240e3b812c212aa814a6209bef6a4a9af74"
    }
  },
  {
    "ts": null,
    "headline": "Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment",
    "summary": "FOSTER CITY, Calif., May 07, 2025--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undet",
    "url": "https://finnhub.io/api/news?id=b0b9f59f757220fc1b1bb550e543c7356fd11e93aa010bf6def544ea40fba14f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746599400,
      "headline": "Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment",
      "id": 134290290,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., May 07, 2025--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undet",
      "url": "https://finnhub.io/api/news?id=b0b9f59f757220fc1b1bb550e543c7356fd11e93aa010bf6def544ea40fba14f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025",
    "summary": "FOSTER CITY, Calif., May 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and stat",
    "url": "https://finnhub.io/api/news?id=41c9434d032c9e714de5305cc70ac976595672bca87a9b0e0a592e7f4e6b6e8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746598500,
      "headline": "Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025",
      "id": 134290291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., May 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and stat",
      "url": "https://finnhub.io/api/news?id=41c9434d032c9e714de5305cc70ac976595672bca87a9b0e0a592e7f4e6b6e8c"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Puritan Fund Q1 2025 Review",
    "summary": "Fidelity Puritan Fund Q1 2025 Review",
    "url": "https://finnhub.io/api/news?id=6b471f2dca1975c8f147a9b7fa8cd36eaccc55c7ee18335e824da6c299169a59",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746577800,
      "headline": "Fidelity Puritan Fund Q1 2025 Review",
      "id": 134288053,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6b471f2dca1975c8f147a9b7fa8cd36eaccc55c7ee18335e824da6c299169a59"
    }
  }
]